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BACKGROUND: There are limited data on health status instruments in patients with peripheral artery disease and cardio-
vascular and limb events. We evaluated the relationship between health status changes and cardiovascular and limb 
events.
METHODS AND RESULTS: In an analysis of the EUCLID (Examining Use of Ticagrelor in Symptomatic Peripheral Artery 
Disease) trial, we examined the characteristics of 13 801 patients by tertile of health status instrument scores collected in 
the trial (EuroQol 5-Dimensions [EQ-5D], EQ visual analog scale [VAS], and peripheral artery questionnaire). We assessed 
the association between the baseline health status measurements and major adverse cardiovascular events, major ad-
verse limb events, and lower-extremity revascularization procedures during trial follow-up and the association between 
12-month health status change scores and subsequent end points during follow-up. There were 13 217 (95%) patients 
with EQ-5D scores, 13 533 (98%) with VAS scores, and 4431 (32%) with peripheral artery questionnaire scores. Patients 
in the lowest baseline EQ-5D tertile (0 to <0.69) were more likely to be female with severe claudication compared with the 
highest tertile (0.79–1.0; P<0.01). Patients in the lowest VAS (0–60) and peripheral artery questionnaire (0–49) tertiles had 
lower ankle–brachial indices compared with the highest tertiles (80–100 and 76–108, respectively; P<0.01). There was a 
significant association between baseline EQ-5D, VAS, and peripheral artery questionnaire scores and adjusted major ad-
verse cardiovascular events, major adverse limb events, and lower-extremity revascularization (P<0.05). Improved EQ-5D 
and VAS scores over 12 months were associated with reduced risk of subsequent major adverse cardiovascular events 
or lower-extremity revascularization (all P<0.01).
CONCLUSIONS: Although health status instruments are rarely used in clinical practice, these measures are associated with 
outcomes, including major adverse cardiovascular events, major adverse limb events, and lower-extremity revasculariza-
tion. Further research is needed to determine the relationship between changes in these instruments, revascularization, and 
outcomes.
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Wide variation exists in the use of health status instruments, or patient-reported outcomes measures, in quantifying outcomes for pa-
tients with peripheral artery disease (PAD). The op-
tions also vary widely from non–disease-specific 
health status instruments, such as the EuroQoL 
5-Dimensions (EQ-5D) and Short Form-36 (SF-36), 
to disease-specific health status instruments, like the 
peripheral artery questionnaire (PAQ), the Intermittent 
Claudication Questionnaire (ICQ), and the Peripheral 
Artery Disease Quality of Life (PADQOL) question-
naires.1–5 The primary utility has been to characterize 
the functional limitations of PAD and how that can be 
improved with exercise training, lower extremity revas-
cularization (LER), and pharmacotherapy.6–9 Many of 
these instruments have been validated only in patients 
with intermittent claudication and may not be appro-
priate to be used in more advanced PAD, such as in 
critical limb ischemia. Furthermore, the performance 
of these health status instruments is inconsistent 
across metrics, such as reliability, internal consis-
tency, and content and construct validity.10 Perhaps 
most importantly, there is scant literature regarding 
how these health status instrument scores change 
over time in the PAD population, and if the scores (and 
changes in scores) are associated with subsequent 
cardiovascular or limb events. Understanding the 
association between these health status scores and 
clinical outcomes would potentially allow for increased 
risk stratification of patients with PAD.
The EUCLID (Examining Use of Ticagrelor in 
Symptomatic Peripheral Artery Disease) trial was a 
multicenter, double-blind, randomized controlled trial 
that examined the effect of ticagrelor versus clopi-
dogrel monotherapy and collected the EQ-5D index 
score and EQ visual analog scale (VAS), as well as the 
PAQ, to examine patient-reported quality of life over 
the course of the trial.11 Because the trial provides 
follow-up data on a large cohort of patients with PAD 
over 30 months, we are able to examine the change 
in EQ-5D and PAQ scores over the trial as well as 
association of the scores with clinical end points. 
The current analysis was conducted to determine: (1) 
the characteristics of patients with PAD stratified by 
health status instrument score tertile, (2) the change 
in health status instrument scores over the course 
of the trial follow-up, (3) the association of the base-
line health status instrument scores with subsequent 
cardiovascular events, and (4) the association of the 
change in health status instrument score over time 
with subsequent cardiovascular events.
METHODS
The authors cannot make data and study materials 
available to other investigators for purposes of repro-
ducing the results because of licensing restrictions. 
Interested parties, however, could obtain and license 
the data by contacting the EUCLID steering commit-
tee and AstraZeneca, United Kingdom.
The EUCLID trial examined the effect of ticagrelor 
versus clopidogrel monotherapy in 13  885 patients 
with symptomatic PAD. The trial was conducted 
from December 2012 to March 2014. Participation 
in the trial was approved by the institutional review 
boards of participating sites. All patients gave writ-
ten informed consent. The trial design and results 
have been previously described.11,12 The trial did not 
demonstrate a benefit for ticagrelor over clopidogrel 
in patients with symptomatic PAD and did not meet 
CLINICAL PERSPECTIVE
What Is New?
• The baseline scores on health status instru-
ments, such as the EuroQol 5-Dimensions, 
visual analog scale, and peripheral artery ques-
tionnaire, were associated with clinical out-
comes, including major adverse cardiovascular 
events, major adverse limb events, and lower-
extremity revascularization.
• Improvement in the EuroQol 5-Dimensions and 
visual analog scales cores over 12 months was 
associated with a reduced risk in subsequent 
major adverse cardiovascular events or lower-
extremity revascularization events.
What Are the Clinical Implications?
• Performance on several readily available health 
status instruments is associated with important 
clinical end points, and consideration should be 
given to using these instruments to care for pa-
tients with peripheral artery disease.
Nonstandard Abbreviations and Acronyms
ALI acute limb ischemia
ABI ankle–brachial index
EQ-5D EuroQol 5-Dimensions
EUCLID  Examining Use of Ticagrelor in 
Symptomatic Peripheral Artery Disease
LER lower-extremity revascularization
MACE major adverse cardiovascular events
MALE major adverse limb events
PAQ peripheral artery questionnaire
SF-36 Short Form-36
VAS visual analog scale
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the primary end point. Patients were enrolled if they 
were at least 50 years of age with symptomatic PAD 
and had either (1) previous revascularization of the 
lower limbs more than 30  days before randomiza-
tion or (2) evidence of PAD as exhibited by an ankle–
brachial index (ABI) ≤0.80. In cases where the ABI 
was ≥1.40, a toe–brachial index of ≤0.60 was used 
as proof of PAD. In the resulting population, 76.6% 
had claudication and 4.6% had critical limb ischemia 
(participants without claudication were mainly those 
with a prior history of LER). The EUCLID publications 
committee approved this secondary analysis with a 
waiver of informed consent.
Health-Related Quality-of-Life Measures
We examined several health status instruments that were 
used to evaluate trial participant’s quality of life at base-
line and on follow-up. The EuroQol-5D (EQ-5D) is a non–
disease-specific patient-reported outcomes measure 
developed by the EuroQol Group.13 It evaluates five di-
mensions of self-reported quality of life, including mobility, 
self-care, usual activities, pain/discomfort, and anxiety/
depression. The EQ VAS is another component which 
asks respondents to indicate on a 20-cm vertical scale 
“the best health you can imagine” and the “worst health 
you can imagine.” The Peripheral Artery Questionnaire 
(PAQ) is a 20-item disease-specific patient-reported 
outcomes measure, which examines physical limitation, 
symptoms, quality of life, social function, and treatment 
satisfaction among patients with PAD.1
Outcomes
The primary composite end points were major adverse 
cardiovascular events (MACE), which was defined as 
the composite of nonfatal myocardial infarction (MI), 
non-fatal ischemic stroke, or cardiovascular death; 
major adverse limb events (MALE), which included 
major amputations and acute limb ischemia (ALI) re-
quiring hospitalization; and LER. The individual compo-
nents of MALE, as well as LER, were further analyzed.
To examine the baseline characteristics of patients 
by health status instrument score tertile, we analyzed 
the population of patients with available baseline 
scores for each of the health status instruments—the 
EQ-5D index score, the EQ-5D VAS, and the PAQ. 
We examined the scores for each of the health sta-
tus instruments at months 12 and 24. Patients who 
did not have available or had negative scores were 
not included in the calculation of the overall mean 
and median scores at each of the trial follow-up pe-
riods. For the analysis examining the association be-
tween change in EQ-5D index score and VAS from 
baseline to 12  months and subsequent outcomes, 
we excluded patients who experienced a clinical 
event of interest prior to the 12-month follow-up and 
those patients who did not complete the EQ-5D at 
12 months.
Statistical Analysis
We examined the baseline characteristics of patients 
enrolled in the trial, stratified by tertile of health sta-
tus instrument. Continuous variables were compared 
using an ANOVA or Kruskal–Wallis test and categorial 
variables were compared using chi-square or Fisher’s 
exact test. We reported continuous variables as me-
dian (25th–75th percentiles) and categorical variables 
as number (%). To examine the trends over time in 
EQ-5D index and VAS, as well as PAQ scores, we 
reported the mean (standard deviation) and median 
(25th–75th percentiles) scores at baseline, 12 months, 
and 24 months.
To examine the association between baseline health 
status instrument scores and clinical events, we de-
veloped Cox proportional hazards models for each of 
the scores—the EQ-5D index score, VAS, and PAQ. 
Adjustment variables are listed in Table S1. All adjustment 
variables were checked for nonlinearity using natural 
cubic splines, and the proportional hazards assumption 
was checked using weighted Schoenfeld residuals. A 
linear relationship can be assumed between health sta-
tus scores and clinical outcomes. We determined which 
variables would be used for adjustment using stepwise 
selection with an inclusion criterion of P=0.05. Hazard 
ratios are presented for each 0.1- or 10-unit increase in 
the health status instrument score. Hazard ratios with 
95% confidence intervals and associated P-values are 
presented for each health status instrument and each 
primary composite or individual end point.
Because of increased missingness in PAQ from 
baseline to 12 months (4431 patients completed the 
PAQ out of the 13 855), we only examined the associ-
ation between change in EQ-5D index and VAS from 
baseline to 12  months and subsequent outcomes. 
The PAQ is a longer, more involved instrument than 
the others, which may explain the increased missing-
ness. We used a Cox proportional hazards model, 
landmarked at 12 months and controlled for the base-
line scores in all unadjusted and adjusted models. For 
each outcome evaluated, patients had to be alive and 
event-free at 12 months to be included in the analy-
sis. We adjusted for the variables listed in Table S1. 
Finally, the linearity assumption was assessed for the 
change in EQ-5D index score and VAS.
RESULTS
Among all patients enrolled in EUCLID, there were 
13 217 patients with complete EQ-5D scores (95.4%), 
13 533 patients with EQ-5D VAS scores (97.7%), and 
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4431 patients with PAQ scores (32.0%). For each 
health status instrument, baseline characteristics are 
demonstrated by tertile of instrument score (Tables S2 
through S4). Patients in the highest EQ-5D index score 
tertile (0.79–1.0) were less likely to be female; less 
likely to have severe claudication, rest pain, or tissue 
loss; and less likely to have a history of stroke, MI, or 
diabetes mellitus, compared with patients in the low-
est score tertile (all P<0.001). Patients in the highest 
EQ-5D VAS score tertile (80–100) were also less likely 
to have severe claudication or tissue loss, compared 
with patients in the lowest tertile (all P<0.001). Finally, 
patients in the highest PAQ score tertile (76–108) were 
less likely to have severe claudication or tissue loss 
and less likely to have a history of coronary artery dis-
ease and diabetes mellitus (all P<0.001).
Change in Health Status Instrument 
Scores Over the Trial Follow-Up
There were 9979 patients with complete EQ-5D index 
scores, 10 443 patients without missing EQ-5D VAS 
scores, and 3225 patients without missing PAQ scores 
at baseline, the 12-month follow-up, and the 24-month 
follow-up. The EQ-5D index score and EQ-5D VAS 
scores remained stable across the 12- and 24-month 
follow-ups (Table  S5). There was an increase in the 
mean and median PAQ scores at both the 12- and the 
24-month follow-up periods. Figure S1A through S1C 
demonstrates the change in health status instrument 
scores at the various time points.
Association of Baseline Health Status 
Scores and Outcomes
There was a significant association between both 
baseline EQ-5D index score and PAQ with MACE 
(EQ-5D—adjusted HR, 0.96; 95% CI, 0.93–0.98; 
PAQ—adjusted HR, 0.92; 95% CI, 0.88–0.96), 
MALE (EQ-5D—adjusted HR, 0.93; 95% CI, 0.88–
0.98; PAQ—adjusted HR, 0.91; 95% CI, 0.84–1.00), 
major amputation (EQ-5D—adjusted HR, 0.91; 95% 
CI, 0.85–0.98; PAQ—adjusted HR, 0.86; 95% CI, 
0.75–0.98) and LER (EQ-5D—adjusted HR, 0.95; 
95% CI, 0.93–0.97; PAQ—adjusted HR, 0.90; 95% 
CI, 0.88–0.93), unadjusted and adjusted P<0.05 
(Tables  1 and 2). For the EQ-5D index score, the 
hazard ratio represents the change in hazard as-
sociated with 0.1-point increase in the EQ-5D scale; 
for the PAQ score, the hazard ratio represents the 
change in hazard associated with a 10-point in-
crease in the PAQ score. For the EQ-5D VAS, there 
was a significant association between baseline 
EQ-5D VAS and unadjusted and adjusted MACE 
(adjusted HR, 0.96; 95% CI, 0.93–0.98), MALE (ad-
justed HR, 0.93; 95% CI, 0.88–0.98), ALI requiring 
hospitalization (adjusted HR, 0.91; 95% CI, 0.85–
0.98), and LER (adjusted HR, 0.94; 95% CI, 0.92–
0.96; P<0.01 for all; Table 3). For the EQ-5D VAS, 
the hazard ratio represents the change in hazard 
associated with a 10-point increase in the EQ-5D 
VAS score. Figures 1 and 2 demonstrate the asso-
ciation of EQ-5D and PAQ scores with MACE and 
MALE, respectively. Figure 3 illustrates the associa-
tion of EQ-5D and PAQ scores with LER. Table S6 
lists the number of clinical events or outcomes by 
tertile for each health status instrument.
Change in EQ-5D and Outcomes
There were 11  913 patients included in this analy-
sis (1669 were excluded because of deaths or 
missing EQ-5D instrument scores at the 12-month 
follow-up period). Table  S7 illustrates the baseline 
Table 1. Association Between EQ-5D Index Score and Outcomes
Clinical Outcome
Unadjusted Adjusted
HR (95% CI) P Value* HR (95% CI) P Value*
MACE† 0.92 (0.90–0.94) <0.0001 0.96 (0.93–0.98) 0.0022
MALE‡ 0.90 (0.86–0.94) <0.0001 0.93 (0.88–0.98) 0.0112
ALI requiring hospitalization§ 0.97 (0.91–1.04) 0.3766 0.96 (0.90–1.03) 0.2827
Major amputation ‖ 0.84 (0.79–0.89) <0.0001 0.91 (0.85–0.98) 0.0094
LER¶ 0.96 (0.94–0.98) 0.0005 0.95 (0.93–0.97) <0.0001
ABI indicates ankle–brachial index; ALI, acute limb ischemia; HR, hazard ratio; EQ-5D, EuroQol 5-Dimensions; LER, lower-extremity revascularization; 
MACE, major adverse cardiovascular events; and MALE, major adverse limb events.
*We used a Cox proportional hazards model, landmarked at 12 months and controlled for the baseline scores in all unadjusted and adjusted models.
†Adjusted for Rutherford score, sex, inclusion criteria, prior carotid revascularization, prior carotid stenosis, diabetes mellitus, angiotensin II receptor blocker 
(ARB) use, prior minor amputation, prior major amputation, statin use and ABI, ticagrelor (study arm).
‡Adjusted for Rutherford score, inclusion criteria, region, prior carotid revascularization, diabetes mellitus, prior aspirin use, prior clopidogrel use, tobacco 
use, ABI, estimated glomerular filtration rate (eGFR), ticagrelor (study arm).
§Adjusted for inclusion criteria, ABI, hypertension, prior carotid revascularization, ARB use, ticagrelor (study arm).
 
‖Adjusted for Rutherford score, inclusion criteria, prior coronary artery bypass graft (CABG), diabetes mellitus, statin use, prior major amputation, prior minor 
amputation, ABI, weight, ticagrelor (study arm).
¶Adjusted for inclusion criteria, region, ABI, tobacco use, diabetes mellitus, prior clopidogrel use, prior aspirin use, ticagrelor (study arm).
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characteristics of the included and excluded popu-
lations. Overall, patients excluded from this analysis 
were clinically similar to the patients included in the 
analysis. The association between change in PAQ 
from baseline to 12  months and outcomes could 
not be assessed due to the missingness of follow-
up PAQ scores. An improvement in EQ-5D index 
scores and the EQ-5D VAS was associated with a 
reduced unadjusted and adjusted risk of MACE (EQ-
5D index—adjusted HR, 0.90; 95% CI, 0.87–0.94; 
EQ-5D VAS—adjusted HR, 0.88; 95% CI, 0.85–0.92) 
and LER events (EQ-5D index—adjusted HR, 0.87; 
95% CI, 0.84–0.90; EQ-5D VAS—adjusted HR, 0.91; 
95% CI, 0.87–0.94; all P<0.01; Table 4) but not with 
adjusted risk of MALE, ALI requiring hospitalization, 
or major amputation.
DISCUSSION
In this subanalysis of a large cohort of patients with 
PAD from the EUCLID trial, we examined the change in 
health status instrument scores over the trial follow-up 
period as well as the association of health status scores 
with subsequent cardiovascular and limb events. 
Patients in the highest score tertile of the EQ-5D or 
PAQ instruments at baseline were significantly more 
likely to be asymptomatic and less likely to have severe 
claudication or tissue loss. Additionally, the EQ-5D 
index scores and VAS remained stable over the trial 
follow-up, while PAQ scores increased. Furthermore, 
baseline EQ-5D and PAQ scores were significantly as-
sociated with composite outcomes, including MACE, 
MALE, and LER. Finally, we demonstrated that an 
Table 2. Association Between PAQ Score and Outcomes
Clinical Outcome
Unadjusted Adjusted
HR (95% CI) P Value* HR (95% CI) P Value*
MACE† 0.88 (0.85–0.91) <0.0001 0.92 (0.88–0.96) <0.0001
MALE‡ 0.91 (0.84–0.98) 0.0101 0.91 (0.83–1.00) 0.0420
ALI requiring hospitalization§ 0.99 (0.90–1.08) 0.8294 0.98 (0.89–1.08) 0.6716
Major amputation‖ 0.83 (0.74–0.92) 0.0006 0.86 (0.75–0.98) 0.0242
LER¶ 0.90 (0.88–0.92) <0.0001 0.90 (0.88–0.93) <0.0001
ALI indicates acute limb ischemia; EQ-5D, EuroQol 5-Dimensions; HR, hazard ratio; LER, lower-extremity revascularization; MACE, major adverse 
cardiovascular events; MALE, major adverse limb events; and PAQ, peripheral artery questionnaire.
*We used a Cox proportional hazards model, landmarked at 12 months and controlled for the baseline scores in all unadjusted and adjusted models.
†Adjusted for Rutherford score, sex, prior stroke, prior carotid revascularization, prior myocardial infarction (MI), prior percutaneous coronary intervention 
(PCI), prior coronary artery bypass graft (CABG), diabetes mellitus, statin use, tobacco use, prior minor amputation, age, ankle–brachial index (ABI), estimated 
glomerular filtration rate (eGFR), ticagrelor (study arm).
‡Adjusted for Rutherford score, inclusion criteria, prior carotid revascularization, diabetes mellitus, prior major amputation, statin use, ABI, region, and 
tobacco use, ticagrelor (study arm).
§Adjusted for inclusion criteria, prior carotid revascularization, statin use, eGFR, ticagrelor (study arm).
‖Adjusted for Rutherford score, prior carotid revascularization, diabetes mellitus, prior major amputation, prior minor amputation, ABI, ticagrelor (study arm).
¶Adjusted for inclusion criteria, region, ABI, tobacco use, prior clopidogrel use, eGFR, ticagrelor (study arm).
Table 3. Association Between EQ-5D VAS Score and Outcomes
Clinical Outcome
Unadjusted Adjusted
HR (95% CI) P Value* HR (95% CI) P Value*
MACE† 0.92 (0.90–0.94) <0.0001 0.96 (0.93–0.98) 0.0018
MALE‡ 0.89 (0.85–0.93) <0.0001 0.93 (0.88–0.98) 0.0088
ALI requiring hospitalization§ 0.89 (0.84–0.95) 0.0002 0.91 (0.85–0.98) 0.0070
Major amputation‖ 0.88 (0.83–0.93) <0.0001 0.93 (0.86–1.00) 0.0535
LER¶ 0.95 (0.93–0.97) <0.0001 0.94 (0.92–0.96) <0.0001
ALI indicates acute limb ischemia; HR, hazard ratio; LER, lower-extremity revascularization; MACE, major adverse cardiovascular event; MALE, major 
adverse limb event; and VAS, visual analog scale.
*We used a Cox proportional hazards model, landmarked at 12 months and controlled for the baseline scores in all unadjusted and adjusted models.
†Adjusted for Rutherford score, sex, inclusion criteria, region, prior stroke, prior carotid revascularization, prior myocardial infarction (MI), prior percutaneous 
coronary intervention (PCI), diabetes mellitus, statin use, tobacco use, prior minor amputation, age, ankle–brachial index (ABI), weight, estimated glomerular 
filtration rate (eGFR), ticagrelor (study arm).
‡Adjusted for Rutherford score, sex, inclusion criteria, prior carotid revascularization, prior carotid stenosis, diabetes mellitus, angiotensin II receptor blocker 
(ARB) use, prior minor amputation, prior major amputation, statin use and ABI, ticagrelor (study arm).
§Adjusted for inclusion criteria, ABI, hypertension, prior carotid revascularization, ARB use, ticagrelor (study arm).
‖Adjusted for Rutherford score, inclusion criteria, prior carotid stenosis, prior carotid revascularization, diabetes mellitus, statin use, prior major amputation, 
prior minor amputation, ABI, weight, ticagrelor (study arm).
¶Adjusted for inclusion criteria, region, ABI, tobacco use, diabetes mellitus, prior clopidogrel use, prior aspirin use, ticagrelor (study arm).
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improvement in EQ-5D over 12  months was associ-
ated with a reduced risk of MACE and LER subse-
quent to 12 months and up to 24 months.
Importantly, we demonstrated that patients in 
the highest score tertiles for both the PAQ and the 
EQ-5D instruments were less likely to have severe 
claudication or tissue loss and less likely to have 
many of the comorbidities oftentimes associated 
with PAD. While many of the disease-specific health 
status instruments, such as the PAQ and VascuQOL, 
have been validated in the PAD population,1,3,10,14–16 
other generic instruments, such as the EQ-5D and 
SF-36,5 have primarily been used to validate many 
PAD-specific health status instruments. It is crit-
ical for health status instruments to fully represent 
the intended disease state or behavior being mea-
sured. This is particularly challenging in PAD, as the 
perception of disease and burden of comorbidities 
often widely varies across patients with objectively 
similar clinical presentations. Indeed, health status 
instrument scores in PAD have also been shown to 
differ across patient populations. For example, de-
spite having similar ABI values, an analysis of the 
PORTRAIT (Patient-Centered Outcomes Related to 
Treatment Practices in Peripheral Arterial Disease: 
Investigating Trajectories) registry demonstrated that 
women were significantly more likely to have lower 
PAQ scores than men.17 This is in line with our find-
ing that women were much less likely to have PAQ 
scores in the highest tertile. Another analysis showed 
that while there was no significant difference in base-
line and follow-up scores between White and Black 
patients who had undergone a peripheral vascular 
intervention, the improvement in scores postinter-
vention, was lower for Black patients.18 Because 
there is increasing interest around trying to define 
which health status instruments are best used in 
various PAD populations (ie, intermittent claudication 
vs critical limb ischemia, clinical research vs clinical 
practice), further work is needed to understand how 
these instruments perform and differ in performance 
among various patient populations and if they accu-
rately represent the breadth of the disease state of 
interest.
Perhaps most importantly though, we were able 
to demonstrate an association between the baseline 
score on the EQ-5D and PAQ instruments and im-
portant clinical end points, such as MACE, MALE, and 
LER. There is little understanding for many of the PAD 
health status instruments about how performance 
Figure 1. Association of baseline EQ-5D index score, EQ-5D VAS, and PAQ scores and risk of MACE.
There is a significant association between the baseline EQ-5D index score, EQ-5D VAS, and the PAQ 
scores and the 1-year probability of MACE. EQ-5D indicates EuroQol 5-Dimensions; MACE, major 
adverse cardiovascular events; PAQ, peripheral artery questionnaire; VAS, visual analog scale.
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is associated with clinical end points and objective 
measures.19 A recent publication using data from the 
PORTRAIT registry demonstrated that the resting and 
exercise ABI were both associated with the PAQ lim-
itations score, and the time to onset of claudication, 
pain-free walking distance, and maximum walking dis-
tance were associated with the PAQ symptoms and 
overall summary score.20 However, another analysis 
of the PAQ score showed it to be weakly associated 
with ABI, Rutherford classification, and hemodynam-
ics.21 An analysis of patients with PAD treated at an 
academic Veterans Administration Medical Center 
demonstrated a significant correlation between ABI 
and time to maximal claudication and the Walking 
Impairment Questionnaire (WIQ) distance and the SF-
36.22 Our analysis provides increasing evidence that 
two commonly used health status instruments used in 
symptomatic PAD may help clinicians and investigators 
better understand the future risk of important clinical 
end points in this patient population.
Additionally, our analysis is novel in the field of PAD 
in that we assessed the association of the change in 
health status scores over time with various relevant clin-
ical end points. We demonstrated that an improvement 
in the EQ-5D and VAS at 12 months were both associ-
ated with a reduced risk of MACE and LER. However, 
as shown in Table 2, MALE and its individual compo-
nents (ALI or major amputation) were not associated 
with health status. Patients who have better health sta-
tus scores are less likely to undergo LER. Validation 
studies of the various health status instruments have 
examined the change in health status scores with 
some measure of clinical improvement,1,10,23,24 but 
have not necessarily addressed how these changes 
might be associated with future risk of cardiovascular 
and limb events. Further work will be needed to de-
termine what threshold of change on each instrument 
would be associated with a reduced risk of MACE or 
LER. This work is obviously complex on the individ-
ual patient level, because some patients may have a 
significant clinical improvement in PAD (improved ABI, 
walking distance, etc.), but may report continued poor 
quality of life secondary to concomitant and comorbid 
medical conditions.
There are several limitations of the current analysis. 
As this was a post hoc analysis, residual confounding 
likely remains. Because we could not analyze patients 
who had not completed the health status instruments 
at baseline or the various follow-up periods, we may 
have not captured the results of these scores in per-
haps a sicker patient population or among patients 
who may have not agreed to fill out the instruments 
Figure 2. Association of baseline EQ-5D index score, EQ-5D VAS, and PAQ scores and risk of MALE.
There is a significant association between the baseline EQ-5D index score, EQ-5D VAS, and the PAQ 
scores and the 1-year probability of MALE. EQ-5D indicates EuroQol 5-Dimensions; MALE, major adverse 
limb events; PAQ, peripheral artery questionnaire; VAS, visual analog scale.D
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for a variety of reasons. We excluded patients with 
a negative EQ-5D score (284 patients of 13  885), 
which may have impacted the results of the analyses. 
There was significant missingness for the PAQ in-
strument, likely because it is a lengthy questionnaire 
and may be less likely to be completed at baseline 
and at follow-up by study participants. Because of 
its increased length, it is possible that patients with 
worse PAD may be less likely to fill it out. We did 
not assess the association of the various instrument 
Figure 3. Association of baseline EQ-5D index score, EQ-5D VAS, and PAQ scores and risk of LER.
There is a significant association between the baseline EQ-5D index score, EQ-5D VAS, and the PAQ 
scores and the 1-year probability of LER. EQ-5D indicates EuroQol 5-Dimensions; LER, lower-extremity 
revascularization; PAQ, peripheral artery questionnaire; VAS, visual analog scale.
Table 4. Association Between Change in the EQ-5D Index Score and VAS From Baseline to 12 Months and Subsequent 
Outcomes
Clinical Outcome
Unadjusted Adjusted
HR (95% CI) P Value HR (95% CI) P Value*
EQ-5D index score
MACE 0.88 (0.85–0.91) <0.01 0.90 (0.87–0.94) <0.01
MALE 0.94 (0.86–1.02) 0.13 0.94 (0.85–1.04) 0.22
ALI requiring hospitalization 0.96 (0.86–1.08) 0.48 0.92 (0.82–1.04) 0.18
Major amputation 0.89 (0.79–1.00) 0.06 0.92 (0.81–1.05) 0.22
LER 0.85 (0.82–0.88) <0.01 0.87 (0.84–0.90) <0.01
EQ-5D VAS
MACE 0.87 (0.84–0.90) <0.01 0.88 (0.85–0.92) <0.01
MALE 0.94 (0.86–1.02) 0.15 0.95 (0.86–1.04) 0.27
ALI requiring hospitalization 0.97 (0.87–1.08) 0.62 0.94 (0.83–1.06) 0.30
Major amputation 0.89 (0.80–1.00) 0.05 0.94 (0.82–1.08) 0.41
LER 0.91 (0.87–0.94) <0.01 0.91 (0.87–0.94) <0.01
ALI indicate acute limb ischemia; EQ-5D, EuroQol 5-Dimensions; HR, hazard ratio; LER, lower-extremity revascularization; MACE, major adverse 
cardiovascular event; MALE, major adverse limb event; PAQ, peripheral artery questionnaire; and VAS, visual analog scale.
*We used a Cox proportional hazards model, landmarked at 12 months and controlled for the baseline scores in all unadjusted and adjusted models.
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subdomains with clinical end points. Additionally, as 
with any clinical trial, the population of enrolled pa-
tients may not be entirely generalizable to a nontrial 
population of patients with PAD, because patients 
enrolled in clinical trials tend to be healthier and re-
ceive more guideline-directed medical therapy. The 
study population in EUCLID was mostly comprised 
of individuals with either asymptomatic PAD (19%) or 
mild to moderate claudication (53%), thus likely to be 
clinically stable from a vascular standpoint at entry. 
Finally, the landmark analysis was based on patients 
alive and event free at 12  months, which may not 
represent a randomized population and as such may 
be biased.
CONCLUSIONS
Health-related quality-of-life instruments are rarely 
used in clinical practice for the treatment of patients 
with PAD. Given the association of the scores of several 
of these instruments and outcomes such as MACE, 
MALE, and LER, consideration should be given to 
using them more frequently in clinical practice. Further 
work is needed to delineate the relationship between 
changes in health status scores, revascularization, and 
outcomes.
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Table S1. Adjustment Variables used for the Cox Proportional Hazards Model by Score and Outcome. 
 EQ-5D Index Score EQ-5D VAS PAQ 
MACE Rutherford score, sex, inclusion 
criteria, region, prior stroke, prior 
carotid revascularization, prior 
MI, prior PCI, prior CABG, 
diabetes, statin use, tobacco use, 
prior major amputation, prior 
minor amputation, age, ABI, 
eGFR 
Rutherford score, sex, inclusion 
criteria, region, prior stroke, prior 
carotid revascularization, prior 
MI, prior PCI, diabetes, statin 
use, tobacco use, prior minor 
amputation, age, ABI, weight, 
eGFR 
Rutherford score, sex, prior 
stroke, prior carotid 
revascularization, prior MI, prior 
PCI, prior CABG, diabetes, statin 
use, tobacco use, prior minor 
amputation, age, ABI, eGFR 
MALE Rutherford score, inclusion 
criteria, prior carotid 
revascularization, prior carotid 
stenosis, diabetes, ARB use, prior 
major or minor amputation, statin 
use, and ABI 
Rutherford score, inclusion 
criteria, prior carotid 
revascularization, prior carotid 
stenosis, diabetes, ARB use, prior 
major or minor amputation, statin 
use, and ABI 
Rutherford score, inclusion 
criteria, prior carotid 
revascularization, diabetes, prior 
major amputation, statin use, 
ABI, region and tobacco use 
Lower extremity 
revascularization 
Inclusion criteria, region, ABI, 
tobacco use, diabetes, prior 
clopidogrel use, prior aspirin use 
Inclusion criteria, region, ABI, 
tobacco use, diabetes, prior 
clopidogrel use, prior aspirin use 
Inclusion criteria, region, ABI, 
tobacco use, prior clopidogrel 
use, eGFR 
Major Amputation Rutherford score, inclusion 
criteria, prior CABG, diabetes, 
statin use, prior major 
amputation, prior minor 
amputation, ABI, weight 
Rutherford score, inclusion 
criteria, prior carotid stenosis, 
prior carotid revascularization, 
diabetes, statin use, prior major 
amputation, prior minor 
amputation, ABI, weight 
Rutherford score, prior carotid 
revascularization, diabetes, prior 
major amputation, prior minor 
amputation, ABI 
Acute limb ischemia 
requiring hospitalization 
Inclusion criteria, ABI, 
hypertension, prior carotid 
revascularization, ARB use 
Inclusion criteria, ABI, 
hypertension, prior carotid 
revascularization, ARB use 
Inclusion criteria, prior carotid 
revascularization, statin use, 
eGFR 
    
 Change in EQ-5D Index 
Score 
Change in EQ-5D VAS N/A 
MACE Rutherford score, sex, inclusion 
criteria, region, prior stroke, prior 
carotid revascularization, prior 
Rutherford score, sex, inclusion 
criteria, region, prior stroke, prior 
carotid revascularization, prior 
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MI, prior PCI, prior CABG, 
diabetes, statin use, tobacco use, 
prior major amputation, prior 
minor amputation, age, ABI, 
eGFR 
MI, prior PCI, diabetes, statin 
use, tobacco use, prior minor 
amputation, age, ABI, weight, 
eGFR 
MALE Rutherford score, inclusion 
criteria, prior carotid 
revascularization, prior carotid 
stenosis, diabetes, ARB use, prior 
major or minor amputation, statin 
use, and ABI 
Rutherford score, inclusion 
criteria, prior carotid 
revascularization, prior carotid 
stenosis, diabetes, ARB use, prior 
major or minor amputation, statin 
use, and ABI 
 
Lower extremity 
revascularization 
Inclusion criteria, region, ABI, 
tobacco use, diabetes, prior 
clopidogrel use, prior aspirin use 
Inclusion criteria, region, ABI, 
tobacco use, diabetes, prior 
clopidogrel use, prior aspirin use 
 
Major Amputation Rutherford score, inclusion 
criteria, prior CABG, diabetes, 
statin use, prior major 
amputation, prior minor 
amputation, ABI, weight 
Rutherford score, inclusion 
criteria, prior carotid stenosis, 
prior carotid revascularization, 
diabetes, statin use, prior major 
amputation, prior minor 
amputation, ABI, weight 
 
Acute limb ischemia 
requiring hospitalization 
Inclusion criteria, ABI, 
hypertension, prior carotid 
revascularization, ARB use 
Inclusion criteria, ABI, 
hypertension, prior carotid 
revascularization, ARB use 
 
ABI indicates ankle brachial index; ARB, angiotensin receptor blocker; CABG, coronary artery bypass grafting; eGFR, estimated 
glomerular filtration rate; EQ-5D, EuroQol-5D; MI, myocardial infarction; PCI, percutaneous coronary intervention; LER, lower 
extremity revascularization; MACE, major adverse cardiovascular event; MALE, major adverse limb event; PAQ, Peripheral Artery 
Questionnaire; VAS, visual analog scale  
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Table S2. Baseline Patient Characteristics by Tertile of EQ-5D Index Score. 
Characteristic 
0.0 to <0.69 
(N=4,231) 
0.69 to <0.79 
(N=4,369) 
0.79 to 1.0 
(N=4,617) P-value 
Age 66, 60-73 66, 60-72 66, 61-72 0.876 
Female 33.1% 26.4% 24.9% <.001 
Weight, kg 78, 67-89 78, 68-89 75, 65-86 <.001 
Inclusion Criteria    <.001 
ABI/TBI 51.4% 47.7% 32.4%  
ABI value, Mean (SD) 0.62 (0.16) 0.62 (0.15) 0.65 (0.14) <.001 
TBI value, Mean (SD) 0.59 (0.27) 0.48 (0.16) 0.49 (0.17) 0.053 
Prior lower extremity revascularization 48.6% 52.3% 67.6%  
ABI value, Mean (SD) 0.73 (0.23) 0.74 (0.22) 0.84 (0.21) <.001 
Limb Symptoms    <.001 
Asymptomatic 8.1% 10.9% 36.3%  
Mild or Moderate Claudication 51.5% 59.8% 50.2%  
Severe Claudication 33.0% 25.8% 11.6%  
Pain while at Rest 4.5% 1.9% 1.1%  
Major or Minor Tissue Loss 3.0% 1.5% 0.9%  
Prior Major Amputation 3.9% 1.8% 1.1% <.001 
Prior PCI 14.8% 15.4% 15.7% 0.457 
Prior CABG 10.6% 11.9% 11.1% 0.147 
Medical History     
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Characteristic 
0.0 to <0.69 
(N=4,231) 
0.69 to <0.79 
(N=4,369) 
0.79 to 1.0 
(N=4,617) P-value 
Stroke 10.5% 7.1% 6.9% <.001 
Prior Myocardial Infarction 20.2% 17.8% 16.3% <.001 
Diabetes 40.9% 38.7% 34.5% <.001 
Hypertension 80.1% 79.5% 75.7% <.001 
Hyperlipidemia 73.6% 77.4% 76.2% <.001 
COPD 13.3% 11.9% 8.4% <.001 
Number of Vascular Beds    <.001 
1 54.7% 55.8% 58.4%  
>2 45.3% 44.2% 41.5%  
Tobacco Use    <.001 
Current 29.6% 32.7% 31.0%  
Former 43.0% 47.1% 51.7%  
Medications Prior to Randomization     
Aspirin 61.2% 68.3% 71.0% <.001 
Clopidogrel 32.4% 29.9% 34.4% <.001 
Statin 69.7% 74.3% 75.4% <.001 
ACE Inhibitor 42.3% 43.4% 37.9% <.001 
ARB 24.1% 24.3% 26.0% 0.068 
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Characteristic 
0.0 to <0.69 
(N=4,231) 
0.69 to <0.79 
(N=4,369) 
0.79 to 1.0 
(N=4,617) P-value 
Cilostazol 13.4% 14.4% 15.6% 0.013 
ABI indicates ankle brachial index; ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker; CABG, coronary 
artery bypass grafting; COPD; chronic obstructive pulmonary disease; kg, kilogram; PCI, percutaneous coronary intervention; SD, 
standard deviation; TBI, toe brachial index 
Continuous variables were compared using an ANOVA or Kruskal Wallis test and categorial variables were compared using chi-
square or Fisher’s exact test. 
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Table S3. Baseline Characteristics by Tertile of EQ-5D VAS Score. 
 
Characteristic 
0 to 60 
(N=4,683) 
61 to 79 
(N=3,866) 
80 to 100 
(N=4,984) P-value 
Age 66, 60-73 66, 60-72 66, 61-72 0.239 
Female 29.3% 26.0% 29.2% <.001 
Weight, kg 77, 66-89 78, 68-89 76, 66-87 <.001 
Inclusion Criteria    <.001 
ABI/TBI 48.2% 46.2% 37.9%  
ABI value, Mean (SD) 0.61 (0.17) 0.63 (0.14) 0.65 (0.14) <.001 
TBI value, Mean (SD) 0.50 (0.19) 0.56 (0.29) 0.51 (0.16) 0.324 
Prior lower extremity revascularization 51.8% 53.8% 62.1%  
ABI value, Mean (SD) 0.73 (0.24) 0.77 (0.23) 0.81 (0.22) <.001 
Limb Symptoms    <.001 
Asymptomatic 10.8% 16.1% 27.6%  
Mild or Moderate Claudication 49.6% 56.7% 54.0%  
Severe Claudication 31.9% 24.0% 15.2%  
Pain while at Rest 4.8% 1.5% 1.8%  
Major or Minor Tissue Loss 2.8% 1.7% 1.2%  
Prior Major Amputation 3.2% 2.0% 2.2% <.001 
Prior Minor Amputation 5.4% 4.4% 3.4% <.001 
Prior PCI 15.8% 14.6% 15.4% 0.302 
Prior CABG 11.6% 10.7% 11.0% 0.374 
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Characteristic 
0 to 60 
(N=4,683) 
61 to 79 
(N=3,866) 
80 to 100 
(N=4,984) P-value 
Medical History     
Stroke 10.8% 7.4% 6.3% <.001 
Myocardial Infarction 19.8% 17.9% 16.6% <.001 
Diabetes 40.2% 38.5% 36.2% <.001 
Hypertension 79.3% 79.0% 76.7% 0.004 
Hyperlipidemia 73.6% 75.7% 77.5% <.001 
COPD 13.6% 11.1% 9.0% <.001 
Number of Vascular Beds    <.001 
1 53.3% 56.9% 59.0%  
>2 46.7% 43.2% 41%  
Tobacco Use    <.001 
Current 31.2% 30.8% 30.9%  
Former 42.7% 48.3% 50.8%  
Medications Prior to Randomization     
Aspirin 64.2% 65.1% 70.2% <.001 
Clopidogrel 32.8% 31.8% 32.2% 0.599 
Statin 70.4% 73.3% 75.4% <.001 
Ace Inhibitor 42.3% 41.4% 39.4% 0.011 
ARB 23.7% 25.1% 25.6% 0.073 
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Characteristic 
0 to 60 
(N=4,683) 
61 to 79 
(N=3,866) 
80 to 100 
(N=4,984) P-value 
Cilostazol 12.9% 14.5% 16.3% <.001 
ABI indicates ankle brachial index; ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker; CABG, coronary 
artery bypass grafting; COPD; chronic obstructive pulmonary disease; kg, kilogram; PCI, percutaneous coronary intervention; SD, 
standard deviation; TBI, toe brachial index 
Continuous variables were compared using an ANOVA or Kruskal Wallis test and categorial variables were compared using chi-
square or Fisher’s exact test. 
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Table S4. Baseline Characteristics by Tertile of PAQ Score. 
 
Characteristic 
0 to 49 
(N=1,479) 
50 to 75 
(N=1,473) 
76 to 108 
(N=1,479) P-value 
Age 66, 60-73 67, 62-73 68, 61-73 <.001 
Female 34.8% 31.0% 28.9% 0.003 
Weight, kg 82, 70-95 80, 69-92 79, 68-90 <.001 
Inclusion Criteria    <.001 
ABI/TBI 31.3% 29.7% 15.6%  
ABI value, Mean (SD) 0.64 (0.17) 0.66 (0.15) 0.67 (0.16) 0.012 
TBI value, Mean (SD) 0.46 (0.15) 0.37 (0.15) 0.37 (0.20) 0.388 
Prior lower extremity revascularization 68.7% 70.3% 84.4%  
ABI value, Mean (SD) 0.77 (0.22) 0.81 (0.21) 0.88 (0.20) <.001 
Limb Symptoms    <.001 
Asymptomatic 5.5% 14.7% 49.6%  
Mild or Moderate Claudication 50.2% 63.7% 44.3%  
Severe Claudication 37.3% 20.0% 4.4%  
Pain while at Rest 5.3% 1.0% 1.2%  
Major or Minor Tissue Loss 1.6% 0.4% 0.6%  
Prior Major Amputation 2.6% 1.2% 1.3% 0.002 
Prior Minor Amputation 3.8% 2.7% 2.1% 0.020 
Prior PCI 27.5% 25.9% 23.7% 0.061 
Prior CABG 20.6% 20.0% 15.4% <.001 
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Characteristic 
0 to 49 
(N=1,479) 
50 to 75 
(N=1,473) 
76 to 108 
(N=1,479) P-value 
Medical History     
Stroke 7.6% 6.7% 5.5% 0.070 
Prior Myocardial Infarction 23.9% 23.2% 19.3% 0.006 
Diabetes 45.2% 39.3% 31.8% <.001 
Hypertension 85.2% 83.7% 80.0% <.001 
Hyperlipidemia 89.9% 88.5% 87.5% 0.110 
COPD 24.7% 17.7% 10.7% <.001 
Number of Vascular Beds    <.001 
1 42.6% 43.3% 49.5%  
>2 57.4% 56.7% 50.5%  
Tobacco Use    0.030 
Current 37.9% 33.6% 32.8%  
Former 50.5% 55.1% 55.0%  
Medications Prior to Randomization     
Aspirin 73.8% 78.3% 81.9% <.001 
Clopidogrel 43.7% 38.5% 42.6% 0.011 
Statin 83.4% 83.4% 85.9% 0.092 
Ace Inhibitor 45.0% 43.0% 43.0% 0.434 
ARB 25.3% 26.1% 23.9% 0.380 
D
ow
nloaded from
 http://ahajournals.org by on O
ctober 14, 2020
Characteristic 
0 to 49 
(N=1,479) 
50 to 75 
(N=1,473) 
76 to 108 
(N=1,479) P-value 
Cilostazol 14.3% 13.8% 9.5% <.001 
ABI indicates ankle brachial index; ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker; CABG, coronary 
artery bypass grafting; COPD; chronic obstructive pulmonary disease; kg, kilogram; PCI, percutaneous coronary intervention; SD, 
standard deviation; TBI, toe brachial index 
Continuous variables were compared using an ANOVA or Kruskal Wallis test and categorial variables were compared using chi-
square or Fisher’s exact test. 
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Table S5. Trends in Health status Measures over the Trial Follow-up. 
Measure Baseline Month 12 Month 24 
EQ-5D Index Score    
N 9979 9979 9979 
Mean (SD) 0.73 (0.19) 0.76 (0.19) 0.76 (0.19) 
Median (IQR) 0.73, 0.66-0.85 0.73, 0.69-0.85 0.73, 0.69-0.85 
EQ-5D Visual Analog Scale    
N 10443 10443 10443 
Mean (SD) 68.7 (19.5) 70.4 (18.7) 70.9 (18.9) 
Median (IQR) 70, 60-80 72, 60-80 75, 60-80 
PAQ    
N 3225 3225 3225 
Mean (SD) 62.97 (24.2) 66.81 (24.3) 67.57 (24.8) 
Median (IQR) 65, 44-83 69, 50-87 71, 50-89 
EQ-5D indicates EuroQol 5-Dimensions; IQR, interquartile range; PAQ, Peripheral Artery Questionnaire; SD, standard deviation 
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Table S6. Number of Clinical Events by Tertile of Health Status Instrument. 
Event Rates by Tertile of Health Status Instrument Score 
Clinical Outcome 
Tertile 1* 
Rate (Events) 
Tertile 2 
Rate (Events) 
Tertile 3 
Rate (Events) 
EQ-5D (N=13,217)    
MACE 5.32 (525) 4.55 (480) 3.58 (405) 
MALE 1.49 (148) 1.13 (121) 0.85 (98) 
ALI Requiring Hospitalization 0.82 (82) 0.60 (65) 0.64 (74) 
Major Amputation 0.86 (86) 0.63 (68) 0.33 (38) 
LER 5.61 (527) 5.84 (588) 4.89 (531) 
VAS (N=13,533)    
MACE 5.72 (624) 4.20 (392) 3.65 (445) 
MALE 1.59 (176) 1.24 (117) 0.81 (101) 
ALI Requiring Hospitalization 0.87 (97) 0.70 (67) 0.51 (64) 
Major Amputation 0.93 (104) 0.66 (63) 0.38 (48) 
LER 6.16 (638) 5.25 (470) 4.99 (583) 
PAQ (N=4,431)    
MACE 7.24 (249) 5.20 (186) 3.48 (129) 
MALE 1.51 (54) 0.87 (32) 0.83 (31) 
ALI Requiring Hospitalization 0.86 (31) 0.57 (21) 0.66 (25) 
Major Amputation 0.75 (27) 0.48 (18) 0.24 (9) 
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Event Rates by Tertile of Health Status Instrument Score 
Clinical Outcome 
Tertile 1* 
Rate (Events) 
Tertile 2 
Rate (Events) 
Tertile 3 
Rate (Events) 
LER 12.8 (392) 9.22 (304) 6.82 (236) 
ALI indicates acute limb ischemia; EQ-5D, EuroQol-5D; HR, hazards ratio; LER, lower extremity revascularization; MACE, major 
adverse cardiovascular event; MALE, major adverse limb event; PAQ, peripheral artery questionnaire; VAS, visual analog scale 
Tertile 1 is defined as 0-<0.69 for EQ-5D Index Score, 0.69-<0.79 for Tertile 2, and from 0.79-1.0 for Tertile 3. Tertile 1 is defined as 
0-60 for VAS, 61-79 for Tertile 2, and 80-100 for Tertile 3. Tertile 1 is defined as 0-49 for PAQ, 50-75 for Tertile 2, and 76-108 for 
Tertile 3.  
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Table S7. Baseline Characteristics of Patients Included vs. Excluded from Change Analysis. 
Characteristic 
Excluded from Analysis 
(N=1669) 
Included in Analysis 
(N=11913) 
Age 68, 62-75 66, 60-72 
Female 29.8% 28.1% 
Weight, kg 76, 65-87 77, 67-88 
Inclusion Criteria   
ABI/TBI 43.9% 43.8% 
Prior lower extremity 
revascularization 
56.1% 56.2% 
Limb Symptoms   
Asymptomatic 16.1% 18.9% 
Mild or Moderate Claudication 47.1% 54.1% 
Severe Claudication 28.4% 22.9% 
Pain while at Rest 4.6% 2.5% 
Minor Tissue Loss 2.9% 1.3% 
Major Tissue Loss 1.0% 0.3% 
Prior Major Amputation 3.5% 2.3% 
Prior Minor Amputation 6.6% 4.1% 
Prior PCI 16.7% 15.1% 
Prior CABG 13.5% 10.8% 
Medical History   
Stroke 9.1% 960 (8.1% 
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Characteristic 
Excluded from Analysis 
(N=1669) 
Included in Analysis 
(N=11913) 
CAD 31.9% 28.3% 
MI 20.6% 17.8% 
Diabetes 41.5% 37.8% 
Hypertension 79.2% 78.1% 
Hyperlipidemia 74.8% 75.8% 
COPD 13.5% 10.8% 
Liver Disease 2.0% 2.0% 
Number of Vascular Beds   
1 53.9% 56.8% 
2 34.3% 33.5% 
3 11.7% 9.8% 
Tobacco Use   
Current 29.9% 31.1% 
Former 46.3% 47.4% 
Medications Prior to Randomization   
Aspirin 66.2% 66.7% 
Clopidogrel 33.6% 32.1% 
Statin 69.6% 73.6% 
ACE Inhibitor 41.3% 41.0% 
ARB 24.0% 24.9% 
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Characteristic 
Excluded from Analysis 
(N=1669) 
Included in Analysis 
(N=11913) 
Cilostazol 16.4% 14.3% 
ABI indicates ankle brachial index; ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker; CABG, coronary 
artery bypass grafting; CAD, coronary artery disease; COPD; chronic obstructive pulmonary disease; kg, kilogram; MI; myocardial 
infarction; PCI, percutaneous coronary intervention; SD, standard deviation; TBI, toe brachial index 
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Figure S1. Boxplot of Change in Health Status Instrument Scores at the 12 Month and 24 
Month Trial Follow-up (1a- EQ-5D, 1b- EQ VAS, 1c- PAQ).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The boxplots illustrate the change in the various health status instruments scores at baseline, 12-
month follow-up and at 24 months follow-up. Each boxplot illustrates the minimum and 
maximum scores, the median score, and the interquartile range.  
 
 
 
A B 
C 
D
ow
nloaded from
 http://ahajournals.org by on O
ctober 14, 2020
